Filter Results:
- Full text PDF available (31)
Publication Year
2008
2018
- This year (17)
- Last 5 years (59)
- Last 10 years (72)
Publication Type
Co-author
Journals and Conferences
Data Set Used
Learn More
- Jonathan E Rosenberg, Jean H. Hoffman-Censits, +28 authors Robert Dreicer
- Lancet
- 2016
BACKGROUND
Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab, an engineered… (More)
- Omid A. Hamid, Caroline Robert, +23 authors Antoni Ribas
- The New England journal of medicine
- 2013
BACKGROUND
The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab… (More)
- Caroline Robert, Antoni Ribas, +22 authors Adil I. Daud
- Lancet
- 2014
BACKGROUND
The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in patients with melanoma. We compared the efficacy… (More)
- John A Jakob, Roland Bassett, +10 authors Michael A. Davies
- Cancer
- 2012
BACKGROUND
There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral… (More)
- Antoni Ribas, Omid A. Hamid, +25 authors Caroline Robert
- JAMA
- 2016
IMPORTANCE
The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.
OBJECTIVE
To characterize the… (More)
- Arjun Vasant Balar, Matthew David Galsky, +32 authors Dean F Bajorin
- Lancet
- 2017
BACKGROUND
First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high… (More)
- Laura A Finn, Svetomir N. Markovic, Richard W. Joseph
- BMC medicine
- 2012
Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements in our understanding of how melanoma evades the immune system as well… (More)
- Jahan S. Khalili, Shujuan Liu, +18 authors Gregory A. Lizee
- Clinical cancer research : an official journal of…
- 2012
PURPOSE
In this study, we assessed the specific role of BRAF(V600E) signaling in modulating the expression of immune regulatory genes in melanoma, in addition to analyzing downstream induction of… (More)
- Richard W. Joseph, Payal Kapur, +8 authors Alexander K. Parker
- Cancer
- 2014
BACKGROUND
The majority of patients diagnosed with clear cell renal cell carcinoma (ccRCC) have low-risk disease with a < 10% chance of ccRCC-specific death. DNA sequencing revealed that mutations in… (More)
- Abhisek Swaika, William Adam Hammond, Richard W. Joseph
- Molecular immunology
- 2015
Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the… (More)